Oruka Therapeutics Inc
ORKAHealthcare|Biotechnology|USA
$86.79
-1.48 (-1.68%)
Tangible Book
$9.64
Upcoming Data Readouts (4)
Jan 2027
Est. completion
P1Healthy Volunteers
ORKA-002-211 A Phase I Study to Evaluate ORKA-002 in Healthy Volunteers Following A Single Dose
NCT06944379n=24
Jun 2027
Est. completion
P2Plaque Psoriasis
Dose Ranging Study of ORKA-001 in Patients With Moderate-to-Severe Plaque Psoriasis
NCT07290569n=160
Oct 2027
Est. completion
P2Plaque Psoriasis
Dose Ranging Study of ORKA-002 in Patients With Moderate-to-Severe Plaque Psoriasis
NCT07474792n=160
May 2030
Est. completion
P2Plaque Psoriasis
An Open-Label Extension Study of ORKA-001 in Participants With Plaque Psoriasis
NCT07449702n=240
Awaiting Results (1)
Trials past primary completion date but still active — data readout may be imminent.